Introduction
Gemcitabine is a nucleoside analog that inhibits cell growth by incorporating into
DNA and prohibiting DNA polymerases. This chemotherapeutic agent is approved for the
treatment of multiple solid tumors. Common side effects include hematologic toxicity,
flu-like symptoms, peripheral edema, and gastrointestinal disturbances.
1
Cutaneous reactions occur in up to 30% of patients but rarely require discontinuation.
2
Reports have surfaced over the years of gemcitabine-induced erysipeloid, pseudocellulitis
reactions, lipodermatosclerosis, and skin necrosis.
3
To our knowledge, only 3 previous reports exist that describe gemcitabine-induced
subacute cutaneous lupus erythematous (SCLE) (Table I).4, 5, 6 We present 2 cases
of SCLE induced by gemcitabine chemotherapy in patients with pancreatic cancer.
Table I
Comparison of case 1 and case 2 with current cases reported in the literature
Case 1
Case 2
Wiznia et al
4
Ben Zvi et al
5
Lam
6
Age
88
67
71
63
73
Sex
F
M
F
F
F
Incubation period
2 wk
1 wk
2 wk
3 d
5 mo
Serology
+ ANA, SSA, SSB
+ ANA, SSA
+ ANA, SSA, SSB
Negative
Negative
Cutaneous features
Red papules and plaques with focal scale of chest and back
Annular and confluent scaly pink plaques face, neck, chest, arms
Scaly erythematous annular plaques of arms, papules of chest
Reddish-violaceous annular-like edematous scaly lesions of lower extremities
Erythematous plaques of scalp, chest, back, arms, legs
Histopathology
Epidermal atrophy, vacuolar interface change, sparse lymphocytic infiltrate; DIF negative
Epidermal necrosis, superficial perivascular lymphocytic infiltrate; DIF negative
Thinned epidermis, dermoepidermal junction vacuolar alteration, superficial and deep
perivascular infiltrate
Effaced rete pegs, vacuolar interface, superficial and deep perivascular mononuclear
lymphocyte infiltrate and dermal mucin deposition
Epidermal atrophy, band-like lymphocytic infiltrate at dermoepidermal junction, vacuolar
degeneration, mild increase in dermal mucin
Outcome
Resolution after discontinuation + topical and oral steroids
Resolution after discontinuation + quinacrine
Resolution after discontinuation + topical and oral steroids
Resolution after discontinuation + oral steroids
Resolution after discontinuation + topical steroids
Time to resolution after discontinuing gemcitabine
3 mo
4 mo
5 wk
Unknown
8 mo
DIF, Direct immunofluorescence.
Case 1
An 88-year-old active, independent woman with hypothyroidism, hypertension, gastroesophageal
reflux disease and atrial fibrillation was referred to a gastroenterologist by her
primary care physician for abdominal pain, distention, pale bowel movements, and jaundice
for 6 weeks. Workup found pancreatic ductal adenocarcinoma. The patient opted for
treatment rather than palliative/hospice care. She was treated with oral capecitabine,
825 mg/m2 twice a day for 14 days of a 21-day cycle, and subsequently dose-attenuated
gemcitabine, 900 mg/m2 intravenously on days 1, 8, and 15 was added. After her second
weekly dose of gemcitabine, pruritic, red papules and plaques with focal scale developed
in a photodistributed pattern; these lesions were centrally confluent on her chest
and back (Fig 1). The lesions did not respond to initial treatment with hydrocortisone
2.5% topical lotion twice daily nor to a methylprednisolone 4-mg dose pack.
Fig 1
Erythematous, papulosquamous changes on the patient's chest after her second weekly
dose of gemcitabine (case 1).
Skin biopsy findings included parakeratosis, hyperkeratosis, epidermal atrophy, vacuolar
interface change, subtle epidermal dysmaturation, and a sparse lymphocytic infiltrate
(Fig 2). Direct immunofluorescence testing was negative. Serologic analysis was positive
for antibodies SS-A, greater than 8 (reference range, <1.0); SS-B, 4.9 (reference
range, <1.0); antinuclear antibodies (ANAs) with a titer of 1:160 (reference range,
<1:40); and a nucleolar pattern supporting a diagnosis of SCLE. Because of the patient's
grade 3 reaction with marked pruritus interfering with her ability to sleep, gemcitabine
was discontinued 2 weeks after the onset of the rash. Triamcinolone 0.1% cream was
also added to her treatment regimen. Capecitabine and rabeprazole were continued.
Her pruritus and rash gradually resolved over the next 3 months; however, both the
ANA titer (1:320) and SS-A titer (>8) remained elevated. Interestingly, the SS-B titer
declined to 1.2.
Fig 2
Interface dermatitis with basilar necrotic keratinocytes, subtle dysmaturation, and
foci of parakeratosis (case 1).
Case 2
A 67-year-old man with a medical history of pulmonary sarcoidosis not on active treatment,
atrial fibrillation, and unspecified connective tissue disease (diagnosed over 7 years
prior based on joint pain, pericardial effusion, and positive ANA/anti-Ro, anti-La
antibodies) presented for unintentional 45-pound weight loss. Pancreatic ductal adenocarcinoma
was the ultimate diagnosis. The patient received 4 infusions of neoadjuvant mFOLFIRINOX
(modified regimen of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) and
underwent distal pancreatectomy and splenectomy. Two months postoperatively he began
adjuvant chemotherapy with gemcitabine and capecitabine. Within 1 week of his first
infusion, he developed a rash, oral ulcers, and fatigue developed. Dermatologic evaluation
found pink plaques with focal central scale (some annular and others more confluent)
of the lateral face with notable sparing of the mid-face, posterior, and lateral neck;
upper chest; and bilateral forearms (Fig 3). There was ulceration of the frenulum
and the gingivae. Laboratory results were notable for pancytopenia with white blood
cell count of 2.65 cells/L; hemoglobin, 11.0 g/dL; and platelet count of 42,000 per
microliter. Serologic analysis was positive for ANA (no titer available) and anti
SS-A antibodies. Anti SS-B antibodies were negative. Histopathology from skin biopsy
of the arm demonstrated interface change with extensive epidermal necrosis, dermal
superficial perivascular lymphocytic infiltrate, and rare eosinophils (Fig 4). Direct
immunofluorescence was negative. Drug-induced SCLE (DI-SCLE) was diagnosed based on
clinical presentation and supportive histopathology and serologies.
Fig 3
Psoriasiform papules coalescing into plaques on the forearm (case 2).
Fig 4
Interface change with extensive epidermal necrosis, dermal superficial perivascular
lymphocytic infiltrate, and rare eosinophils (case 2).
Capecitabine was felt to be the most likely culprit and was discontinued. The patient
began topical clobetasol and resumed chemotherapy with gemcitabine and abraxane. However,
the patient's rash flared after receiving the infusion. This re-exposure confirmed
that gemcitabine was actually the culprit medication, and gemcitabine was subsequently
discontinued. The rash persisted after medication was discontinued for 6 weeks, which
is not uncommon for DI-SCLE but is less common in phototoxic skin reactions. The patient
was initiated on quinacrine, as he had a history of retinopathy secondary to hydroxychloroquine,
which had been discontinued 2 years before this evaluation. The patient's chemotherapy
was transitioned to FOLFIRI (5-fluorouracil, irinotecan, and leucovorin calcium).
Within 4 months of follow-up the patient's rash completely resolved with hypo- and
hyperpigmentation.
Discussion
SCLE is a subset of cutaneous lupus erythematosus that is characterized by a nonscarring
papulosquamous rash, photosensitivity, and anti-Ro/SS-A antibodies. Over the last
decade, there has been an increasing number of drugs implicated as triggers for DI-SCLE,
most notably antihypertensive drugs, such as calcium channel blockers, angiotensin-converting
enzyme inhibitors, and antifungals. Chemotherapeutics have also been implicated in DI-SCLE
including fluorouracil, capecitabine, doxetaxel, paclitaxel, doxorubicin, gemcitabine,
and the selective estrogen receptor modulator, tamoxifen.
4
The pathogenesis of DI-SCLE is not fully understood. In particular, it is hypothesized
that chemotherapeutic agents can induce SCLE through induction of apoptosis, leading
to nucleosome release, which then act as target antigens and induce an autoimmune
response.
7
Gemcitabine is a nucleoside analog that leads to apoptosis through replacement of
cytosine in DNA replication and through inactivation of ribonucleotide reductase.
Thus, it is reasonable to speculate that similar to other chemotherapeutic agents
implicated in DI-SCLE, gemcitabine stimulates an exacerbated immune response through
increased levels of apoptotic products.
SCLE can present weeks to years after medication initiation with a photoexacerbated
psoriasiform or annular, scaly rash. It is classically distributed on the chest (V
pattern), upper back, shoulders, and neck. The lateral face can be involved, but the
central face is typically spared. Although drug-induced SCLE is usually clinically
indistinguishable from the nonmedication-related cases, it has been reported to have
higher predilection for the face and lower extremities and more commonly presents
with cutaneous vasculitis and bullous lesions. Laboratory findings include positive
ANA, and positive anti-SSA in up to 90% of cases. Anti-SSB antibodies may be positive
in a lower percentage of cases. Skin biopsy shows interface dermatitis with vacuolization
of the basal layer and perivascular lymphocytic infiltrate, and direct immunofluorescence
may or may not be positive for IgG, IgM, and C3 at the dermoepidermal junction. Eosinophils
may be present in both DI-SCLE and SCLE but cannot be used to differentiate the 2
conditions.
8
The rash typically resolves with medication cessation, and the serologies may fluctuate
over time.
Our patients' new-onset rashes presented in a photodistributed pattern. For case one,
the presentation was striking in that it developed in early spring, with the presence
of cold temperatures and limited sun exposure. Case 2 presented in early summer. Given
these patterns, a photo-recall phenomenon was also considered, particularly because
gemcitabine has been reported as a culprit.
9
Photo-recall reactions are similar to radiation-recall reactions, in which an eruption
occurs on areas of previous ultraviolet-induced sunburn or radiation damage, respectively.
Clinical findings for photo-recall resemble an exaggerated sunburn reaction, with
confluent bright red erythema sharply demarcated from sun-protected sites. There may
be superimposed blisters. Photo-recall reactions have been reported after administration
of multiple medications.
10
Although interface dermatitis with necrotic keratinocytes has been documented in photo-recall
reactions, the patients' clinical presentations with papulosquamous and annular lesions
and positive ANA, SS-A, and, in case one, SS-B antibodies, are more consistent with
SCLE.11, 12 In case 2, the patient's history of positive ANA and autoimmune diathesis
may have predisposed him to DI-SCLE. Additionally, the recurrence of skin eruption
with rechallenge further supports the diagnosis of DI-SCLE.
The distinction between photo-recall and SCLE is important. Photo-recall occurs on
previously sunburned skin, usually 1 to 8 days after drug administration. It does
not typically spare the mid-face. It does not usually recur with drug rechallenge
and may be managed with topical/systemic corticosteroids and photo-protective measures.11,
13 DI-SCLE can be managed similarly, but resolution of symptoms requires discontinuation
of the offending agent.12, 14 In previous reports of chemotherapy-induced photo-recall,
ANA, anti-Ro, and anti-La were not always measured.
11
It is important that serologic analysis of antibodies be performed after a drug-induced
rash to help distinguish between the 2 diseases.
The incubation period between medication initiation and rash onset is varied in DI-SCLE
and is medication dependent. In both of our patients, the onset of cutaneous symptoms
was soon after gemcitabine initiation, after the second and first infusions, respectively.
These incubation periods are similar to those in cases of gemcitabine-induced SCLE
reported by Wiznia and colleagues.
4
Both patients presented in this report were simultaneously taking the chemotherapeutic
agent capecitabine, which has also been implicated in DI-SCLE.15, 16 Determining which
agent is the most likely medication culprit is a challenge. In case 1, the chronology
of administration made gemcitabine more likely. In case 2, capecitabine was felt to
be the more likely agent, given the higher number of cases reported in the literature,
and was discontinued first; however, resolution occurred only after discontinuation
of gemcitabine.
Spontaneous resolution of DI-SCLE commonly occurs within 6 to 12 weeks of drug withdrawal,
and Ro/SS-A titers decrease within 8 months in most patients.
17
Administration of topical corticosteroids can accelerate the process and provide symptomatic
relief.
18
Full resolution can vary as apparent by our cases and can require additional therapy.
In case 2, quinacrine was added to hasten disease resolution.
Our cases add to the literature on gemcitabine-induced SCLE. Gemcitabine is a commonly
used chemotherapeutic agent. Cutaneous side effects of all grades are common and require
discontinuation in less than 1% of cases.
2
However, physicians should be aware of the rare presentation of photodistributed DI-SCLE,
as discontinuation of the causative drug is indicated. This type of case requires
close multidisciplinary care with oncology and dermatology departments.